Sandoz Gmbh

Novartis Ag

Rudolf Markstein

Peter Gull

Max Peter Seiler

Esteban Pombo Villar

Robert Swoboda

Jose Palacios

The invention provides a compound of formula Iwherein A, B, X, Y and Rare as defined in the description, and a process for preparing them. The compounds of formula I are useful as pharmaceuticals.

Benzo [g] quinoline derivatives for treating glaucoma and myopia

Benzo[g]quinoline derivatives

Compounds of formula I ##STR1## wherein A, B, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are as defined in the description, are useful for the treatment of conditions where prevention or delay of progressive atrophy of the optic nerve is desirable.

Benzo�G!quinolines for use in prevention or delay of progressive atrophy

6-hydroxy or 6-alkoxy-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoxalines bearing in position 4 an optionally substituted phenyl group may be used in the treatment of schizophrenia, drug abuse or self-injurious behavior.

Benzoquinoxalines, pharmaceutical compositions containing them and their

The invention relates to the compound of formula I ##STR1## in free base form or in acid addition salt form its preparation and use as a medicament for glaucoma, depression, Morbus Parkinsonism or cocaine abuse.

Octahydrobenzo[g]quinoline

Selective dopamine D1 receptor agonists for use in the treatment of primary degenerative dementia, depression, anxiety, obesity or schizophrenia.

Growing community of inventors

Rheinfelden, Germany

Rudolf Markstein